Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellegy reports positive Tostrelle data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cellegy has begun preparations to move its testosterone gel product Tostrelle into Phase III following discussions with FDA and a positive interim analysis of a Phase II trial in postmenopausal women with low testosterone levels and sexual dysfunction symptoms. The 103-patient, four-month study showed a 65% improvement in number of satisfying sexual events (a 30% increase over placebo). Serum testosterone levels were also brought into normal physiologic range (p<0.001). Cellegy has halted enrollment in the Phase II trial...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel